becton dickinson compani
bullish model updat post
bullish
host bdx presid ceo tom polen evp cfo chri reidi last week
part virtual healthcar confer think could trade higher near term
news flow test vaccin regard model consensu model
revenu could littl low given revenu high singl
digit april consensu model quarter consensu estim
assum increas revenu increas earn
level think seem reason perhap even conserv given potenti
test vaccin knee revenu contribut fiscal none
three contribut lower elect procedur may still weigh legaci bard
busi see upsid risk number
believ stand rel compani cover updat model adjust
result comment firesid chat ep estim
within percentag point consensu
test could know viabil bdx new point care antigen test
within next week given bdx comment capac potenti
revenu per test antigen test could potenti contribut
 per quarter sale late year ramp product anticip
launch reiter timelin fluid given speed product
brought market view test could avail june test
accuraci success valid syring activ ramp capac
conjunct discuss govern pharma manufactur produc
syring covid vaccin deliveri month could produc increment
syring roughli opportun accord
convers bdx ceo last week pleas see call transcript
think also strongli posit benefit numer potenti chang
med-tech post-covid includ acceler point care test use mail
order pharmaci transit outpati consolid laboratori
reiter buy rate
full definit iqmethod sm measur see page
net dbt
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
becton dickinson compani
becton dickinson co bd diversifi global
medic technolog compani produc
medic devic instrument system reagent
healthcar life scienc research clinic
diagnost pharmaceut market bd
grown larg medic conglomer
significantli expand compani medic
technolog footprint infus medic
well regard provid medic
suppli diagnost life scienc tool
seri growth profit initi
result better organ sale ep growth
led multipl expans acquisit
carefus bard provid
unmatch portfolio new growth
plu organ revenu growth
becton dickinson compani may
becton dickinson compani
price object base ep estim multipl
line larg cap peer think warrant given long term growth
profil mid-singl digit
downsid risk po increas competit slower growth emerg
market price eros lower healthcar util trend soft uptak new
diagnost product slower growth hospit capit spend
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
becton dickinson compani may
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
becton dickinson compani may
